Clinical trial
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
NCT05095376 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
- Lead sponsor
- NRG Oncology
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- March 28, 2022
- Completion date
- February 12, 2031
- Enrollment
- 265 (actual)
- Sites
- 420
Conditions
As the registry lists them; a condition with its own page is linked.